iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 902,500 shares, a growth of 98.7% from the February 13th total of 454,200 shares. Based on an average daily volume of 395,800 shares, the days-to-cover ratio is currently 2.3 days. Approximately 9.7% of the shares of the company are short sold.

iBio Stock Performance

Shares of IBIO opened at $5.08 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a fifty-two week low of $1.05 and a fifty-two week high of $6.89. The business has a 50 day simple moving average of $3.45.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.